http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
-
Dare Bioscience (DARE) Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream
-
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
-
Dare Bioscience (DARE) Announces Board Changes
-
Daré Bioscience Announces Executive Team and Board of Directors Changes
-
Dare Bioscience (DARE) Announces Grant to Support Biotherapeutic Product Development
-
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
-
Dare Bioscience (DARE) DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
-
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
-
Dare Bioscience (DARE) Secures $12M in Royalty-backed Investment Structure
-
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
-
Dare Bioscience (DARE) Reports Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Study
-
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
-
Dare Bioscience (DARE) Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DA
-
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB
-
Dare Bioscience (DARE) Announces FDA Clearance of IND Application for DARE-VVA1
-
Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vul
-
Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
-
Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs
-
Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting
-
Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
-
Daré Bioscience to Participate in Three November Conferences
-
Daré Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023
-
Dare Bioscience (DARE) Reports Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream
-
Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program
-
Dare Bioscience (DARE) Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO Vaginal Gel, 2%
-
Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in F
-
Dare Bioscience (DARE) Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
-
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
-
Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting
-
Daré Bioscience to Participate in Upcoming Investor Conferences
-
Daré Bioscience Completes Previously Announced Equity Financing
-
Dare Bioscience (DARE) Announces 10M Share Offering at $0.70/sh
-
Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
-
Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
-
Dare Bioscience (DARE) Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Tri
-
Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of
-
Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023
-
Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth
-
Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems
-
Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women
-
Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
-
Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vagino
-
Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Pos
-
Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference
-
Dare Bioscience (DARE) Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1
-
Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 - a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy - in Climacteric, t
-
Dare Bioscience (DARE) Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study
-
Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
-
Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference
